IP Library Granted Patent US 11,331,273
Granted Patent B2
US 11,331,273 · App. 16/089,544 · Granted May 17, 2022

Film-coated tablet having high chemical stability of active ingredient

Inventors: Mitsuhiro Matono (Osaka, JP); Tetsuya Hayama (Osaka, JP)
A61K9/2826A61K9/284A61K9/2866A61K31/575
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,331,273
App. No.
16/089,544
Granted
May 17, 2022
Kind
B2
Abstract

The present invention relates to a film-coated tablet having a high chemical stability of an active ingredient, said film-coated tablet comprising: (a) a tablet core containing obeticholic acid or a pharmaceutically acceptable salt thereof; and (b) a coating layer, which is provided on the surface of the tablet core, containing a film base and being substantially free from any plasticizer or containing at least one kind of specific plasticizer.

Claims (15)

1. A film-coated tablet containing obeticholic acid or a pharmaceutically acceptable salt thereof, comprising:

(a) an uncoated tablet containing obeticholic acid or a pharmaceutically acceptable salt thereof, and

(b) a film base on the surface of said uncoated tablet, comprising a coating layer which contains at least one type of specific plasticizer selected from a group consisting of: triethyl citrate, lecithin, glycerin fatty acid ester, propylene glycol, triacetin, polyoxyethylene sorbitan fatty acid ester, concentrated glycerin, sorbitan fatty acid ester, sorbitol, glycerin, diethyl phthalate, dibutyl sebacate, tributyl citrate, diethyl sebacate, acetylated monoglyceride, acetyl triethyl citrate, acetyl tributyl citrate, monostearin dioctyl phthalate, butyl phthalyl butyl glycolate and medium chain fatty acid triglycerides; wherein the plasticizer does not comprise polyethylene glycol.

2. The film-coated tablet of claim 1 , wherein the sorbitan fatty acid ester is sorbitan sesquioleate or sorbitan monolaurate.

3. The film-coated tablet of claim 1 , wherein the glycerin fatty acid ester is glyceryl monostearate.

4. The film-coated tablet of claim 1 , wherein the polyoxyethylene sorbitan fatty acid ester is polyoxyethylene sorbitan monooleate.

5. The film-coated tablet of claim 1 , wherein the specific plasticizer is selected from a group consisting of triethyl citrate, propylene glycol and triacetin.

6. The film-coated tablet of claim 1 , wherein the specific plasticizer is triethyl citrate.

7. The film-coated tablet of claim 1 , wherein the amount of the specific plasticizer included is 0.1 to 30% by weight.

8. The film-coated tablet of claim 1 , wherein the coating layer which includes at least one type of the specific plasticizer includes at least one type of film base selected from a group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, polyvinyl alcohol-based resin, polyvinyl pyrrolidone and methacrylic acid copolymer.

9. The film-coated tablet of claim 1 , wherein the coating layer which includes at least one type of the specific plasticizer includes at least one type of film base selected from a group consisting of hydroxypropyl methyl cellulose and polyvinyl alcohol-based resin.

10. The film-coated tablet of claim 8 , wherein the polyvinyl alcohol-based resin is any of polyvinyl alcohol, a polyvinyl alcohol derivative, a polyvinyl alcohol copolymer or a mixture thereof.

11. The film-coated tablet of claim 8 , wherein the polyvinyl alcohol-based resin is polyvinyl alcohol.

12. The film-coated tablet of claim 1 , wherein the coating layer which includes at least one type of the specific plasticizer includes a hydroxypropyl methyl cellulose film base.

13. The film-coated tablet of claim 8 , wherein the amount of the film base included is 30 to 98% of the coating layer by weight.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0990 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
Priority Claims (1)
JP JP2016-071408 · Mar 31, 2016 · national
Continuity (1)
Related Publication 20200268671A1 · Aug 27, 2020